Nursing2024 Drug Handbook

lansoprazole 845

immune-related reaction is suspected or an alternative cause can’t be identified. • Look alike–sound alike: Don’t confuse lam- otrigine with lamivudine or levothyroxine. Don’t confuse Lamictal with Lamisil, labetalol, or Lomotil. PATIENT TEACHING Alert: Counsel family member or care- givers to monitor patient for changes in be- havior and to immediately report suicidality. • Instruct patient or caregiver to report wors- ening of seizures. • Inform patient that drug may cause rash, especially if administered with valproic acid. Tell patient to report rash or signs or symp- toms of hypersensitivity promptly to pre- scriber; drug may need to be stopped. • Strongly advise patient to visually inspect tablets with each prescription refill to verify the tablets are correct, to avoid medication errors. • Caution patient to report all medications being taken or changes to medications, espe- cially oral contraceptives or other hormone products. • Warn patient not to engage in hazardous activity until drug’s CNS effects are known. • Advise patient to seek immediate medical attention if signs or symptoms of HLH oc- cur, including fever; rash; abdominal pain, tenderness, or swelling; enlarged lymph nodes; yellowing of the skin or eyes; unusual bleeding; seizures; vision changes; or trouble walking. • Teach patient or caregiver to immediately report headache, fever, mouth ulcers, bruising or petechiae, signs of infection (fever, cough, dyspnea), neck stiffness, nausea, vomiting, rash, drowsiness, confusion, or light sensitiv- ity. • Warn patient that the drug may trigger sen- sitivity to the sun and to take precautions until tolerance is determined. • Warn patient not to stop drug abruptly. Alert: Advise patient of childbearing poten- tial to discuss drug therapy with prescriber if considering pregnancy. Alert: Caution patient to seek immediate medical attention for abnormal heart rate or irregular rhythm, or such signs or symptoms as racing heartbeat, skipped or slow heart- beat, shortness of breath, dizziness, or faint- ing.

lansoprazole lanz-AH-pray-zol Prevacid i

Therapeutic class: Antiulcer drugs Pharmacologic class: PPIs AVAILABLE FORMS Capsules (delayed-release) : 15 mg , 30 mg Tablets (ODT delayed-release): 15 mg, 30 mg INDICATIONS & DOSAGES Adjust-a-dose (for all indications): Recom- mended dosage in patients with severe he- patic impairment (Child-Pugh class C) is 15 mg PO daily. ➤ Short-term treatment of active duode- nal ulcer Adults: 15 mg PO daily before eating for 4 weeks. ➤ Maintenance of healed duodenal ulcers Adults: 15 mg PO daily. ➤ Short-term treatment of active benign gastric ulcer Adults: 30 mg PO once daily for up to 8 weeks. ➤ Short-term treatment of erosive esophagitis Adults: 30 mg PO daily before eating for up to 8 weeks. If healing doesn’t occur, 8 more weeks of therapy may be given. Maintenance dosage for healing is 15 mg PO daily. Children ages 12 to 17: 30 mg PO once daily for up to 8 weeks. Children ages 1 to 11 weighing more than 30 kg: 30 mg PO once daily for up to 12 weeks. Children ages 1 to 11 weighing 30 kg or less: 15 mg PO once daily for up to 12 weeks. ➤ Long-term treatment of pathologic hypersecretory conditions, including Zollinger-Ellison syndrome Adults: Initially, 60 mg PO once daily. In- crease dosage, as needed. Give daily amounts above 120 mg in evenly divided doses. ➤ Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence Adults: For patients receiving dual therapy, 30 mg PO lansoprazole with 1 g PO amox- icillin, each given t.i.d. for 14 days. For pa- tients receiving triple therapy, 30 mg PO lansoprazole with 1 g PO amoxicillin and

L

i Photoguide

Canada

OTC Off-label use

Do not crush *Liquid contains alcohol

Genetic